- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Germany Hesitates Over the World's First $1 Million Drug
German health authorities are debating whether the price of Europe's first approved gene therapy is worth the $1 million price tag.
German health authorities are debating whether the price of Europe's first approved gene therapy is worth the $1 million price tag.
The price tag for UniQure NV of Amsterdam's Glybera reflects the fact that it is given just once and targes a disease that afflicts only 200 people in Europe. Germany's Federal Joint Committee has asked for more data on safety and efficacy before it starts a new assessment in June 2016. Glybera has not been submitted to US regulators yet.
UniQure's chief executive officer, Jorn Aldag, told Bloomberg Business that the cost of Glybera should be compared with other orphan drugs that target rare diseases. On average these drugs cost about $250,000 a year, but with a study of 19 patients showing that Glybera was effective over 6 years, the drug's $1 million price tag is equivalent to less than $170,000 a year, Bloomberg reported.
Read more at Bloomberg Business: http://bloom.bg/1Ah2M9E
Muscle-Directed Therapy Apitegromab Meets Primary End Point in Phase 3 SAPPHIRE Trial of SMA
October 17th 2024Patients aged 2-21 receiving apitegromab showed clinically meaningful motor function improvements, with a favorable safety profile consistent with long-term data, as Scholar Rock prepares for US and EU regulatory submissions in Q1 2025.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
New Research Unearths Evidence of Global Metabolic Disruption in Patients With SMA
September 21st 2024A recent analysis investigated the state of metabolic disruption experienced by patients with spinal muscular atrophy (SMA), adding to the literature on nutritional and metabolic complications linked to SMA.
Read More
